US Federal Senate Bill SB3325

US Federal 2025-2026 Regular Session

• Introduced: 12/3/25
• Refer: 12/3/25

Caption

Expanding Access to Affordable Drugs and Medical Devices Act

Impact

The proposed legislation will potentially lower costs and increase access to essential drugs and medical devices. By creating a framework for these organizations to operate under tax-exempt status, the bill promotes the manufacturing and distribution of affordable medical products aimed at addressing significant public health needs. This may lead to enhanced competition and innovation in the healthcare sector, ultimately benefiting consumers with more accessible healthcare options.

Summary

SB3325, titled the 'Expanding Access to Affordable Drugs and Medical Devices Act', seeks to amend the Internal Revenue Code of 1986 to establish criteria for determining the tax-exempt status of organizations that manufacture and distribute drugs and medical devices aimed at meeting public health needs. The bill recognizes organizations as public interest drug or medical device health care organizations, allowing them to maintain their tax-exempt status under specific conditions that emphasize affordability and public benefit.

Contention

Notably, discussions around SB3325 may involve debates concerning the balance between corporate interests and public welfare. Critics may argue about the effectiveness of the bill in actually achieving lower prices for drugs and devices, or question the mechanisms that determine what qualifies as a 'public interest' organization. There are concerns regarding potential abuses of tax exemptions and the implications of regulating such organizations effectively to ensure they prioritize health outcomes over profit.